HuGE Literature Finder
Records 1-9
|
[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
Zhonghua zhong liu za zhi [Chinese journal of oncology] 2016 Nov 38 (11): 868-873. Wei J, Qian X P, Zou Z Y, Wang L F, Yu L X, You C W, Song Y, Lu H Y, Hu W J, Yan J, Xu X X, Chen X F, Li X Y, Wu Q F, Zhou Y, Zhang F L, Liu B |
|
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
The Lancet. Oncology 2016 Sep . Ledermann Jonathan A, Harter Philipp, Gourley Charlie, Friedlander Michael, Vergote Ignace, Rustin Gordon, Scott Clare, Meier Werner, Shapira-Frommer Ronnie, Safra Tamar, Matei Daniela, Fielding Anitra, Spencer Stuart, Rowe Philip, Lowe Elizabeth, Hodgson Darren, Sovak Mika A, Matulonis Ursu |
|
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
|
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
The Lancet. Oncology 2015 Jan 16 (1): 87-97. Oza Amit M, Cibula David, Benzaquen Ana Oaknin, Poole Christopher, Mathijssen Ron H J, Sonke Gabe S, Colombo Nicoletta, Špa?ek Ji?í, Vuylsteke Peter, Hirte Holger, Mahner Sven, Plante Marie, Schmalfeldt Barbara, Mackay Helen, Rowbottom Jacqui, Lowe Elizabeth S, Dougherty Brian, Barrett J Carl, Friedlander Micha |
|
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
|
The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
Oncology 2013 85 (5): 278-82. Huszno Joanna, Budryk Magdalena, Ko?osza Zofia, Nowara El?bie |
|
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
The Lancet. Oncology 2011 Sep 12 (9): 852-61. Gelmon Karen A, Tischkowitz Marc, Mackay Helen, Swenerton Kenneth, Robidoux André, Tonkin Katia, Hirte Hal, Huntsman David, Clemons Mark, Gilks Blake, Yerushalmi Rinat, Macpherson Euan, Carmichael James, Oza Am |
|
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Lancet (London, England) 2010 Jul 376 (9737): 235-44. Tutt Andrew, Robson Mark, Garber Judy E, Domchek Susan M, Audeh M William, Weitzel Jeffrey N, Friedlander Michael, Arun Banu, Loman Niklas, Schmutzler Rita K, Wardley Andrew, Mitchell Gillian, Earl Helena, Wickens Mark, Carmichael Jam |
|
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Lancet (London, England) 2010 Jul 376 (9737): 245-51. Audeh M William, Carmichael James, Penson Richard T, Friedlander Michael, Powell Bethan, Bell-McGuinn Katherine M, Scott Clare, Weitzel Jeffrey N, Oaknin Ana, Loman Niklas, Lu Karen, Schmutzler Rita K, Matulonis Ursula, Wickens Mark, Tutt Andr |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 27, 2021
- Content source: